Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing government focus on localizing pharmaceutical production
3.2.1.2 Increasing prevalence of chronic and infectious diseases
3.2.1.3 Rising investment in healthcare infrastructure and research
3.2.2 Industry pitfalls & challenges
3.2.2.1 Lack of a comprehensive regulatory framework for biosimilars and biologicals
3.2.2.2 High costs associated with monoclonal antibody production and procurement
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Future market trends
3.7 Porter’s analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Humanized
5.3 Fully human
5.4 Chimeric
5.5 Other types
Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Oncology
6.3 Autoimmune diseases
6.4 Infectious diseases
6.5 Other applications
Chapter 7 Market Estimates and Forecast, By End User, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Hospitals
7.3 Specialty centers
7.4 Other end users
Chapter 8 Company Profiles
8.1 AbbVie
8.2 Alexion Pharmaceuticals
8.3 Amgen
8.4 Boehringer Ingelheim International
8.5 BIOCAD
8.6 Biogen
8.7 Bristol Myers Squibb
8.8 Eli Lilly and Company
8.9 F. Hoffmann-La Roche
8.10 Generium
8.11 GlaxoSmithKline
8.12 Johnson & Johnson
8.13 Merck
8.14 Nanolek
8.15 Novartis
8.16 Pfizer
8.17 Regeneron Pharmaceuticals
8.18 R-Pharm
8.19 Sanofi
8.20 Takeda Pharmaceutical Company
